MRI Study of Blood-brain Barrier Function in CADASIL
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
Diffusion prepared pseudo-continuous ASL (DP-pCASL) is a newly proposed MRI method to noninvasively measure the function of blood-brain barrier (BBB). The investigators aim to investigate whether the water exchange rate across the BBB, estimated with DP-pCASL, is changed in patients with CADASIL, and to analyze the association between BBB water exchange rate and MRI/clinical features in these patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 70
Healthy Volunteers: t
View:
• Patients with CADASIL confirmed by gene or/and skin biopsy.
• The age range is 20-70 years old.
• There is no contraindication to MRI examination, and the informed consent is signed.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Chen Ling, PhD
lnyy.chen@foxmail.com
+86 18101358135
Time Frame
Start Date: 2021-04-01
Estimated Completion Date: 2026-04-01
Participants
Target number of participants: 100
Treatments
CADASIL patients
Inclusion Criteria:~1. Patients with CADASIL confirmed by gene or/and skin biopsy.~2. The age range is 20-70 years old.~3. There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~2. CADASIL is not confirmed.~3. There are contraindications to examination or refusal to sign the informed consent.
Healthy controls
Inclusion Criteria:~1. The age range is 20-70 years old.~2. There is no contraindication to MRI examination, and the informed consent is signed.~exclusion criteria：~1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases.~2. There are contraindications to examination or refusal to sign the informed consent.
Related Therapeutic Areas
Sponsors
Collaborators: Chinese Academy of Sciences
Leads: Peking University First Hospital